secwatch.observer — SEC 8-K summary
======================================

Issuer:     BiomX Inc. (PHGE)
CIK:        0001739174
Form:       8-K
Filed at:   2026-04-01T23:59:59+00:00
Accession:  0001213900-26-038095
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.55
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BiomX secures option to buy defense-tech DFSL; $5M convertible note plus equity stakes up to 19.99%
--------------------------------------------------------------------------------

- Option to purchase 100% of Mandragola's DFSL shares; exercise after Mandragola acquires 60% of DFSL.
- Consideration: $100K cash, $5M convertible note, preferred stock for 9.9% of common, pre-funded and 5-year warrants at $12 exercise for up to 19.99%.
- Closing subject to Israel Innovation Authority approval of DFSL ownership transfer and standard conditions.
- If DFSL annual revenue reaches $25M+ from FY2027, Mandragola receives 5% revenue bonus in cash or restricted stock.
- BiomX will seek shareholder approval for issuance of >19.99% of common on conversion/exercise; proxy statement to be filed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1739174/000121390026038095/0001213900-26-038095-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1739174/000121390026038095/ea0284436-8k_biomx.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-038095

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer